A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)
A Multicenter, Cross-sectional Study to Evaluate Plasma ApoB-48 Concentration Among Korean Diabetic Patients (With Normal to Moderately High LDL-C Levels)
Sponsor: Organon and Co
Listed as NCT01333436, this NA trial focuses on Dyslipidemia and Hypercholesterolemia and remains completed. Sponsored by Organon and Co, it has been updated 12 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2024 — Jul 2024 [monthly]
Completed NA
-
Jan 2023 — Jun 2024 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Mar 2022 — Dec 2022 [monthly]
Completed NA
-
Jan 2021 — Mar 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jun 2017 — Jun 2018 [monthly]
Completed NA
-
Feb 2017 — Jun 2017 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Organon and Co
For direct contact, visit the study record on ClinicalTrials.gov .